Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia (Mafia)
Cd45 (Yth-24 and Yth 54) and Cd52 (Campath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia
Sponsor: Baylor College of Medicine
Terminated
slow accrual
Other terminated trials from Baylor College of Medicine
Other Fanconi Anemia trials with similar outcome
This PHASE1/PHASE2 trial investigates Fanconi Anemia and Severe Aplastic Anemia and is currently terminated or withdrawn. Baylor College of Medicine leads this study, which shows 10 recorded versions since 2001 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE1_PHASE2
-
Oct 2021 — Dec 2022 [monthly]
Terminated PHASE1_PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Feb 2020 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Jul 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baylor College of Medicine
- Center for Cell and Gene Therapy, Baylor College of Medicine
- The Methodist Hospital Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .